FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2804468749> ?p ?o ?g. }

• W2804468749 endingPage "25253" @default.
• W2804468749 startingPage "25244" @default.
• W2804468749 abstract "// Kym I.E. Snell 1 , Douglas G. Ward 2 , Naheema S. Gordon 2 , James C. Goldsmith 2 , Andrew J. Sutton 3 , Prashant Patel 4 , Nicholas D. James 2 , Maurice P. Zeegers 5 , K.K. Cheng 6 and Richard T. Bryan 2 1 Centre for Prognosis Research, Research Institute for Primary Care and Health Science, Keele University, Newcastle-under-Lyme, ST5 5BG, UK 2 Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK 3 Leeds Institute of Health Sciences, University of Leeds and The Diagnostic Evidence Cooperative, Leeds LS2 9JT, UK 4 Institute of Cancer and Genomic Sciences, University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2TH, UK 5 NUTRIM School for Nutrition and Translational Research in Metabolism and CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht 6200 MD, The Netherlands 6 Institute of Applied Health Research, University of Birmingham, Birmingham B15 2TT, UK Correspondence to: Richard T. Bryan, email: r.t.bryan@bham.ac.uk Keywords: HAI-1; EpCAM; EGFR; bladder cancer; prognosis Received: February 16, 2018      Accepted: April 28, 2018      Published: May 18, 2018 ABSTRACT Objectives: To investigate whether elevated urinary HAI-1, EpCAM and EGFR are independent prognostic biomarkers within non-muscle-invasive bladder cancer (NMIBC) patients, and have utility for risk stratification to facilitate treatment decisions. Results: After accounting for EAU risk group in NMIBC patients, the risk of BC-specific death was 2.14 times higher (95% CI: 1.08 to 4.24) if HAI-1 was elevated and 2.04 times higher (95% CI: 1.02 to 4.07) if EpCAM was elevated. The majority of events occurred in the high-risk NMIBC group and this is where the biggest difference is seen in the survival curves when plotted for EAU risk groups separately. In MIBC patients, being elevated for any of the three biomarkers was significantly associated with BC-specific mortality after accounting for other risk factors, HR = 4.30 (95% CI: 1.85 to 10.03). Patients and Methods: Urinary levels of HAI-1, EpCAM and EGFR were measured by ELISA in 683 and 175 patients with newly-diagnosed NMIBC and MIBC, respectively, recruited to the Bladder Cancer Prognosis Programme. Associations between biomarkers and progression, BC-specific mortality and all-cause mortality were evaluated using univariable and multivariable Cox regression models, adjusted for European Association of Urology (EAU) NMIBC risk groups. The upper 25% of values for each biomarker within NMIBC patients were considered as elevated. Exploratory analyses in urine from MIBC patients were also undertaken. Conclusion: Urinary HAI-1 and EpCAM are prognostic biomarkers for NMIBC patients. These biomarkers have potential to guide treatment decisions for high-risk NMIBC patients. Further analyses are required to define the roles of HAI-1, EpCAM and EGFR in MIBC patients." @default.
• W2804468749 created "2018-06-01" @default.
• W2804468749 creator A5016227054 @default.
• W2804468749 creator A5019418803 @default.
• W2804468749 creator A5019434322 @default.
• W2804468749 creator A5019779203 @default.
• W2804468749 creator A5022378006 @default.
• W2804468749 creator A5030275035 @default.
• W2804468749 creator A5049252097 @default.
• W2804468749 creator A5055733545 @default.
• W2804468749 creator A5062752259 @default.
• W2804468749 creator A5087497984 @default.
• W2804468749 date "2018-05-18" @default.
• W2804468749 modified "2023-10-03" @default.
• W2804468749 title "Exploring the roles of urinary HAI-1, EpCAM & EGFR in bladder cancer prognosis & risk stratification" @default.
• W2804468749 cites W1571103639 @default.
• W2804468749 cites W1841030365 @default.
• W2804468749 cites W1970908071 @default.
• W2804468749 cites W1972447744 @default.
• W2804468749 cites W1980949199 @default.
• W2804468749 cites W1986438764 @default.
• W2804468749 cites W1995622987 @default.
• W2804468749 cites W2002045993 @default.
• W2804468749 cites W2004563844 @default.
• W2804468749 cites W2029681269 @default.
• W2804468749 cites W2079913429 @default.
• W2804468749 cites W2085826031 @default.
• W2804468749 cites W2120021002 @default.
• W2804468749 cites W2120560958 @default.
• W2804468749 cites W2135220383 @default.
• W2804468749 cites W2156611910 @default.
• W2804468749 cites W2411216637 @default.
• W2804468749 cites W2916183155 @default.
• W2804468749 doi "https://doi.org/10.18632/oncotarget.25397" @default.
• W2804468749 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5982738" @default.
• W2804468749 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29861867" @default.
• W2804468749 hasPublicationYear "2018" @default.
• W2804468749 type Work @default.
• W2804468749 sameAs 2804468749 @default.
• W2804468749 citedByCount "12" @default.
• W2804468749 countsByYear W28044687492018 @default.
• W2804468749 countsByYear W28044687492019 @default.
• W2804468749 countsByYear W28044687492020 @default.
• W2804468749 countsByYear W28044687492021 @default.
• W2804468749 countsByYear W28044687492022 @default.
• W2804468749 countsByYear W28044687492023 @default.
• W2804468749 crossrefType "journal-article" @default.
• W2804468749 hasAuthorship W2804468749A5016227054 @default.
• W2804468749 hasAuthorship W2804468749A5019418803 @default.
• W2804468749 hasAuthorship W2804468749A5019434322 @default.
• W2804468749 hasAuthorship W2804468749A5019779203 @default.
• W2804468749 hasAuthorship W2804468749A5022378006 @default.
• W2804468749 hasAuthorship W2804468749A5030275035 @default.
• W2804468749 hasAuthorship W2804468749A5049252097 @default.
• W2804468749 hasAuthorship W2804468749A5055733545 @default.
• W2804468749 hasAuthorship W2804468749A5062752259 @default.
• W2804468749 hasAuthorship W2804468749A5087497984 @default.
• W2804468749 hasBestOaLocation W28044687491 @default.
• W2804468749 hasConcept C121608353 @default.
• W2804468749 hasConcept C126322002 @default.
• W2804468749 hasConcept C142724271 @default.
• W2804468749 hasConcept C143998085 @default.
• W2804468749 hasConcept C161191863 @default.
• W2804468749 hasConcept C2780352672 @default.
• W2804468749 hasConcept C41008148 @default.
• W2804468749 hasConcept C502701156 @default.
• W2804468749 hasConcept C512399662 @default.
• W2804468749 hasConcept C71924100 @default.
• W2804468749 hasConceptScore W2804468749C121608353 @default.
• W2804468749 hasConceptScore W2804468749C126322002 @default.
• W2804468749 hasConceptScore W2804468749C142724271 @default.
• W2804468749 hasConceptScore W2804468749C143998085 @default.
• W2804468749 hasConceptScore W2804468749C161191863 @default.
• W2804468749 hasConceptScore W2804468749C2780352672 @default.
• W2804468749 hasConceptScore W2804468749C41008148 @default.
• W2804468749 hasConceptScore W2804468749C502701156 @default.
• W2804468749 hasConceptScore W2804468749C512399662 @default.
• W2804468749 hasConceptScore W2804468749C71924100 @default.
• W2804468749 hasIssue "38" @default.
• W2804468749 hasLocation W28044687491 @default.
• W2804468749 hasLocation W28044687492 @default.
• W2804468749 hasLocation W28044687493 @default.
• W2804468749 hasLocation W28044687494 @default.
• W2804468749 hasLocation W28044687495 @default.
• W2804468749 hasLocation W28044687496 @default.
• W2804468749 hasOpenAccess W2804468749 @default.
• W2804468749 hasPrimaryLocation W28044687491 @default.
• W2804468749 hasRelatedWork W1916624198 @default.
• W2804468749 hasRelatedWork W1975217245 @default.
• W2804468749 hasRelatedWork W1979321249 @default.
• W2804468749 hasRelatedWork W2042254975 @default.
• W2804468749 hasRelatedWork W2415761310 @default.
• W2804468749 hasRelatedWork W2474195589 @default.
• W2804468749 hasRelatedWork W2588194483 @default.
• W2804468749 hasRelatedWork W2919897224 @default.
• W2804468749 hasRelatedWork W2980122556 @default.
• W2804468749 hasRelatedWork W2118673085 @default.
• W2804468749 hasVolume "9" @default.

• next